167 related articles for article (PubMed ID: 28964667)
1. Removal of a sequestrum by a patient with medication-related osteonecrosis of the jaw.
Davies M; Power A; Kanatas A
Br J Oral Maxillofac Surg; 2017 Nov; 55(9):980-981. PubMed ID: 28964667
[No Abstract] [Full Text] [Related]
2. Bisphosphonate-related osteonecrosis of the jaws--a case report.
Kamoh AK; Ogle O
Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases.
De Santis GC; de Macedo LD; Orellana MD; Innocentini LMAR; Ferrari TC; Ricz HMA; Caruso SR; Fernandes TR; Covas DT
Acta Oncol; 2020 Jul; 59(7):789-792. PubMed ID: 32079438
[No Abstract] [Full Text] [Related]
4. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
5. Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws.
Giovannacci I; Meleti M; Manfredi M; Merigo E; Fornaini C; Bonanini M; Vescovi P
Minerva Stomatol; 2016 Aug; 65(4):248-52. PubMed ID: 27374363
[No Abstract] [Full Text] [Related]
6. Further analyses of the Myeloma IX Study.
Morgan GJ
Lancet; 2011 Aug; 378(9793):768-9. PubMed ID: 21872746
[No Abstract] [Full Text] [Related]
7. Radiology quiz case. Osteonecrosis of the jaw: aminobisphosphonate epidemic.
Junquera L; Gallego L; Villarreal P
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1229-31. PubMed ID: 19015457
[No Abstract] [Full Text] [Related]
8. Zoledronic acid for all patients with newly diagnosed multiple myeloma?
Terpos E; Dimopoulos MA
Lancet Oncol; 2011 Aug; 12(8):711-2. PubMed ID: 21771569
[No Abstract] [Full Text] [Related]
9. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
[TBL] [Abstract][Full Text] [Related]
10. The care and management of bisphosphonate--associated osteonecrosis of the jaw in the patient with multiple myeloma: a case study.
Teah MJ; Syme SL; Scheper M; Weikel DS
J Dent Hyg; 2013 Aug; 87(4):181-7. PubMed ID: 23986411
[TBL] [Abstract][Full Text] [Related]
11. Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw.
Hewson I; Syme D; Bruscino-Raiola F
Aust Dent J; 2012 Jun; 57(2):227-30. PubMed ID: 22624766
[TBL] [Abstract][Full Text] [Related]
12. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
Lee CY; Suzuki JB
Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
[TBL] [Abstract][Full Text] [Related]
13. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Lacy MQ; Dispenzieri A; Gertz MA; Greipp PR; Gollbach KL; Hayman SR; Kumar S; Lust JA; Rajkumar SV; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Bergsagel PL; Fonseca R; Reeder CB; Stewart AK; Roy V; Dalton RJ; Carr AB; Kademani D; Keller EE; Viozzi CF; Kyle RA
Mayo Clin Proc; 2006 Aug; 81(8):1047-53. PubMed ID: 16901028
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-related osteonecrosis of the skull base.
Khan AM; Sindwani R
Laryngoscope; 2009 Mar; 119(3):449-52. PubMed ID: 19235747
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma identified within the same site of the mandible with medication-related osteonecrosis of jaw: An unusual case report.
Wu XH; Chen SW
Medicine (Baltimore); 2023 Jul; 102(29):e34260. PubMed ID: 37478232
[TBL] [Abstract][Full Text] [Related]
17. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
[No Abstract] [Full Text] [Related]
18. Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model.
Barba-Recreo P; Del Castillo Pardo de Vera JL; Georgiev-Hristov T; Ruiz Bravo-Burguillos E; Abarrategi A; Burgueño M; García-Arranz M
J Craniomaxillofac Surg; 2015 Sep; 43(7):1161-8. PubMed ID: 26027865
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis related to once-yearly zoledronic acid treatment in an osteoporotic patient after dental implant.
Miniello TG; Araújo JP; Lopes RN; Alves FA
Braz Dent J; 2015; 26(1):86-8. PubMed ID: 25672391
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.
Fusco V; Loidoris A; Colella G; Vescovi P; Campisi G
Breast; 2010 Oct; 19(5):432-3; author reply 433-4. PubMed ID: 20363135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
